Rafael Muniz Selected Research

Dexmethylphenidate Hydrochloride

7/2013	Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
10/2012	A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
8/2009	Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
3/2009	Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
6/2008	Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
2/2008	Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
1/2008	Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
1/2008	A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
6/2007	Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
7/2006	Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rafael Muniz Research Topics

Disease

16	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 07/2013 - 01/2003
3	Rheumatoid Arthritis 03/2021 - 01/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020
1	Necrosis 01/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Anaphylaxis (Anaphylactic Shock) 01/2018
1	Chromosome Aberrations (Chromosome Abnormalities) 06/2009
1	Abdominal Pain (Pain, Abdominal) 01/2008
1	Headache (Headaches) 01/2008

Drug/Important Bio-Agent (IBA)

11	Dexmethylphenidate Hydrochloride FDA LinkGeneric 07/2013 - 06/2006
9	Methylphenidate (Ritalin)FDA LinkGeneric 07/2013 - 01/2003
3	Adalimumab (Humira)FDA Link 03/2021 - 01/2020
3	Biosimilar PharmaceuticalsIBA 03/2021 - 01/2020
2	FKB327IBA 11/2020 - 01/2020
2	MYL-1501DIBA 01/2020 - 01/2019
2	Insulin Glargine (Lantus)FDA Link 01/2020 - 01/2019
2	Insulin (Novolin)FDA Link 01/2020 - 01/2019
2	Therapeutic UsesIBA 01/2008 - 12/2006
1	Biological ProductsIBA 03/2021
1	Antirheumatic Agents (DMARD)IBA 03/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	Epinephrine (Adrenaline)FDA LinkGeneric 01/2018
1	Amphetamine (Amfetamine)FDA LinkGeneric 09/2010
1	SaltsIBA 09/2010
1	ZeinIBA 06/2009

Therapy/Procedure

1	Therapeutics 01/2018